Halozyme Therapeutics (NASDAQ:HALO) Stock Price Up 5.9% After Analyst Upgrade

Key Points

• Halozyme shares rose 5.9% after TD Cowen raised its price target from $105 to $130 and maintained a Buy rating. Analysts’ consensus view is “Moderate Buy,” although the average price target is $96.50.
• The company reported strong quarterly results, with EPS of $2.28 versus the $1.79 consensus and revenue of $481 million, up 47.7% year over year. Halozyme issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Institutional investors own 97.79% of the stock, while insiders have sold 125,852 shares worth approximately $13.5 million over the past 90 days, including sales by the CEO and a director under pre-arranged trading plans.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) shares rose 5.9% during trading on Wednesday after TD Cowen raised their price target on the stock from $105.00 to $130.00. TD Cowen currently has a buy rating on the stock. Halozyme Therapeutics traded as high as $116.60 and last traded at $116.0910. 395,771 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 1,923,478 shares. The stock had previously closed at $109.62.

Other equities research analysts have also issued research reports about the company. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. HC Wainwright increased their target price on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. Wall Street Zen upgraded Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Citizens Jmp lifted their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $96.50.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 18,996 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the transaction, the director owned 58,839 shares in the company, valued at approximately $6,339,313.86. This trade represents a 24.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE bought a new position in Halozyme Therapeutics in the second quarter worth approximately $214,504,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $196,540,000. Congress Asset Management Co. increased its holdings in shares of Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock valued at $251,890,000 after acquiring an additional 1,052,509 shares in the last quarter. Royal London Asset Management Ltd. increased its holdings in shares of Halozyme Therapeutics by 12.4% during the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company's stock valued at $141,732,000 after acquiring an additional 200,262 shares in the last quarter. Finally, First Trust Advisors LP increased its holdings in shares of Halozyme Therapeutics by 46.5% during the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company's stock valued at $95,804,000 after acquiring an additional 470,558 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Price Performance

The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The business has a 50-day moving average price of $107.30 and a two-hundred day moving average price of $83.87. The company has a market capitalization of $13.24 billion, a price-to-earnings ratio of 34.67, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. Halozyme Therapeutics's quarterly revenue was up 47.7% compared to the same quarter last year. During the same period last year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.